First New Chemical Entity (NCE) approved for PD patients with motor fluctuations in the U.S.A. in over a decade

24 March 2017

Milan, Italy and Morristown, NJ, U.S.A., – March 21, 2017 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain, and its partners Zambon S.p.A. and US WorldMeds, LLC, announced today that the Food and Drug Administration (FDA) has approved the use of Xadago® (safinamide) for the treatment of Parkinson’s disease as add-on therapy to levodopa/carbidopa. Parkinson’s disease affects an estimated 7 to 10 million patients worldwide, of whom 1 million are in the U.S.A.

Main activities

Other activities

First New Chemical Entity (NCE) approved for PD patients with motor fluctuations in the U.S.A. in over a decade

Progetto Talenti

Cultura e salute